MARKET WIREYahoo Finance • 15h ago
Zoetis (ZTS) Stock May Trade At A Discount As Q2 Pressure PersistsYahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
Why ZTS Stock advanced +1.17% Today — RQD Quant Desk Flash
$79.72 +1.17% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $79.74
Zoetis Inc. (ZTS) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $32.56B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZTS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Zoetis Inc. (NYSE: ZTS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $79.72 (+1.17% 1D, market cap $32.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, ZTS ranks #106 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZTS compare to GMAB and RPRX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZTS carries a Roarable C+ (67/100 RQD), trailing P/E of 12.2x, gross margin of 71.8%, and ROIC of 25.7%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.25B) and RPRX (Royalty Pharma plc (Class A)) posts a B grade (75/100 RQD, P/E 49.2x, ROIC 7.0%, cap $37.91B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZTS?
▼
Per ZTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001555280), Zoetis Inc. generated $9.47B in revenue (+2.3% YoY), $2.67B in net income, and $2.28B in free cash flow against $15.49B in total assets and $9.04B in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $79.74 (+0.02%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 24.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE+4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZTS)Realized 20D OHLCV Swing Band: ±4.7%
Deterministic 5-Pillar Attribution (67/100 Composite)
🔍 WHY ZTS SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (27% of score)
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)
▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 24.1% FCF Margin ($2.28B FCF) & 71.8% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)
Macro rate sensitivity & RSI-14 (56.6) create a -13 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$74.30+7.7% Next Q
59
Q2 (-2Q)Grade C+$80.04-2.3% Next Q
62
Q3 (-1Q)Grade C+$78.23+1.9% Next Q
64
CurrentGrade C+$79.72+1.6% Hist 90D α
67
Trajectory: C (59) → C+ (67)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the ZTS Bull Thesis Could Fail
Even with a 67/100 (C+) score, ZTS faces multiple-compression risk if 12.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 69.3% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($75.10) or 200D SMA ($93.06) invalidates the momentum regime and cuts Target Base ($82.95) toward Bear Floor ($64.70).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZTS Stock advanced +1.17% Today — RQD Quant Desk Flash
Zoetis Inc. (ZTS) advanced +1.17% to $79.72, trading at 14% of its 52-week range ($68.77 – $144.83). Solid 72% profit margin (26% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 14% of its 52-week range ($68.77 – $144.83) with RSI-14 at 56.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.7% around $79.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 71.8% gross margin and $2.3B annual free cash flow.
Live ZTS Headlines & Catalysts
CATALYSTTrefis • 18h ago
Can Zoetis Stock Jump 30%?Trefis report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 21h ago
Zoetis: Weakening Fundamentals Overshadow The Discount (NYSE:ZTS)Seeking Alpha report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should KnowYahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Zoetis Inc (ZTS) Stock Up 4.2% and Still Undervalued -- GF Score: 71/100GuruFocus report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 1d ago
Zoetis (NYSE:ZTS) Dividend Quality Backed by Strong Profitability and Health RatingsChartMill report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
3 Reasons ZTS is Risky and 1 Stock to Buy InsteadYahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Zoetis (ZTS) Board Update And Dividend Keep Undervalued Narrative In FocusYahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 12h ago
IDEXX Soars 20% on Beat-and-Raise Quarter: “Early Innings of a Broad-Based Innovation Cycle”Key TakeawaysIDEXX Laboratories shares jumped 20% after a third-quarter beat and a raised 2026 outlook. New inVue Dx analyzers are driving recurring test revenue, with in-clinic consumables up 15% organically.
CATALYSTYahoo • 16h ago
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (ZTS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.25%⚡ TESTING RESISTANCE
2026-11-02O $77.80H $79.72L $77.80C $79.72VOL 2.94M
RES: $83.00SUP: $67.87SMA50: $75.10SMA200: $93.06
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
2.8%/yr Implied 5Y Growth
vs. +2.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZTS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZTS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZTS)
Health Care Rank #106 of 1016
⚔️ GMAB vs ZTS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZTS vs. GMAB, RPRX, ROIV, UTHR)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Zoetis Inc. (ZTS) ranks #106 by composite RQD confidence (67/100, grade C+) and #56 by equity capitalization ($32.56B). Within this direct 5-issuer industry benchmark cohort, ZTS leads on earnings valuation at 12.2x trailing P/E, while ZTS leads on capital efficiency and profitability with 25.7% ROIC and 71.8% gross margin. UTHR currently holds the highest overall quantitative score in the immediate peer group at 82/100 (A-) compared with ZTS at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZTS
ACTIVE
Zoetis Inc. | C+ | 67/100 | 12.2x | 71.8% | 25.7% | +1.17% | $32.56B | Benchmark Subject |
| GMAB Genmab A/S ADS | B- | 70/100 | 32.8x | — | 9.9% | +1.01% | $35.25B | /gmab-vs-zts → |
| RPRX Royalty Pharma plc (Class A) | B | 75/100 | 49.2x | — | 7.0% | +1.90% | $37.91B | /rprx-vs-zts → |
| ROIV Roivant Sciences Ltd. | D | 44/100 | — | — | -14.0% | -1.63% | $27.10B | /roiv-vs-zts → |
| UTHR United Therapeutics Corporation | A- | 82/100 | 19.1x | 87.9% | 20.1% | +0.87% | $25.46B | /uthr-vs-zts → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001555280In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zoetis Inc. (ZTS) reported GAAP revenue of $9.47B (+2.3% vs. FY2024 revenue of $9.26B , and +10.8% cumulative change since FY2023) , GAAP net income of $2.67B, operating cash flow of $2.90B, and free cash flow of $2.28B (-0.7% YoY). On the balance sheet, ZTS closed FY2025 with $15.49B in total assets against $9.04B in total debt (Altman Z-Score: 4.53, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.47B | $2.67B | $2.90B | $2.28B | $15.49B | $9.04B |
| FY2024 (FY) | 2024-12-31 | $9.26B | $2.49B | $2.95B | $2.30B | $14.24B | $5.22B |
| FY2023 (FY) | 2023-12-31 | $8.54B | $2.34B | $2.35B | $1.97B | $17.91B | $4.19B |
3. ZTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Zoetis Inc. (NYSE: ZTS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $79.72 (+1.17% 1D, market cap $32.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, ZTS ranks #106 in composite RQD confidence.
How does ZTS compare to GMAB and RPRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZTS carries a Roarable C+ (67/100 RQD), trailing P/E of 12.2x, gross margin of 71.8%, and ROIC of 25.7%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.25B) and RPRX (Royalty Pharma plc (Class A)) posts a B grade (75/100 RQD, P/E 49.2x, ROIC 7.0%, cap $37.91B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZTS?
Per ZTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001555280), Zoetis Inc. generated $9.47B in revenue (+2.3% YoY), $2.67B in net income, and $2.28B in free cash flow against $15.49B in total assets and $9.04B in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZTS trading relative to its 50-day, 200-day, and 52-week technical levels?
ZTS last traded at $79.72 (+1.17% on volume of 4,118,156 shares), positioning the stock +6.15% above its 50-day simple moving average ($75.10) and -14.33% below its 200-day simple moving average ($93.06). Across its 52-week range of $68.77 to $144.83, ZTS sits at the 14.4% percentile with a 14-day RSI of 56.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.7% ($75.97 to $83.47).
ZTS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZTS stock moving today?
Why ZTS Stock advanced +1.17% Today — RQD Quant Desk Flash. Solid 72% profit margin (26% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 67/100 (C+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ZTS — Zoetis Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:12:12Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ZTS scores 67 out of 100 (letter grade C+, verdict "Roarable Hold — Upper Neutral / Watch for Breakout"). The five pillars are:
- Fundamental Cash Engine: 17 / 20. Per the RQD rating, this reflects ROIC of 25.7% and an FCF yield of 7.01%. For a prospective investor, this is the strongest pillar: the business earns a high return on invested capital and converts a meaningful share of its market value into free cash flow. The tradeoff is that the pillar measures current economics, not whether those economics persist.
- Whale / 13F Flow: 10 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. The score is middling. The source data does not contain 13F detail (see Analyst View section), so the score cannot be traced to specific holder activity here.
- Insider Conviction: 18 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. This is the highest-scoring pillar, which suggests insider and congressional activity skews constructive. The underlying transactions are not itemized in the source data, so investors should verify the composition of that flow independently.
- Macro Regime Fit: 7 / 20. Per the RQD rating, this reflects a beta of 0.99 and sector sensitivity. A beta near 1.0 means the stock has historically moved roughly in line with the market, offering limited defensive cushioning. This is the weakest pillar and signals that the stock's return path depends heavily on broader market conditions.
- Forensic Balance Sheet: 15 / 20. Per the RQD rating, this reflects an Altman Z-Score of 4.53, a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 2.65. The Z-Score and F-Score point to solid financial health, while the elevated leverage ratio is a counterweight that a prospective investor should weigh carefully.
Taken together, the rating frames ZTS as a high-quality operator whose valuation and leverage are reasonable, but whose upside depends on a catalyst that would improve macro regime fit or institutional demand. The "Watch for Breakout" label implies the rating sees the setup as neutral with potential for change rather than a clear buy or sell signal.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $9467.0M | $3154.1M | $2673.0M | N/A | $2283.0M | $2450.0M | $9042.0M |
| FY 2024 | $9256.0M | $2933.5M | $2486.0M | N/A | $2298.0M | $1987.0M | $5220.0M |
| FY 2023 | $8544.0M | $2765.9M | $2344.0M | N/A | $1968.5M | N/A | $4190.7M |
Per the SEC financials, revenue grew from $8544.0M in FY 2023 to $9467.0M in FY 2025, and net income rose from $2344.0M to $2673.0M over the same span. Net margin is 28.2% and ROIC is 25.7% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 4.53 and the Piotroski F-Score is 7/9. Debt rose from $4190.7M in FY 2023 to $9042.0M in FY 2025, and the Debt/Equity ratio is 2.65 per the RQD rating, so the balance sheet has taken on meaningfully more leverage even as cash generation held up. Free cash flow was $2283.0M in FY 2025 against $2298.0M in FY 2024, essentially flat.
Open Questions
- What drove the Q2 pressure referenced in the news feed, and is it expected to persist?
- What products and customer segments generate the reported revenue, and how concentrated is that revenue?
- What is the composition of the insider and congressional flow behind the 18/20 insider score?
- Why did debt rise from $4190.7M to $9042.0M over two years, and what is the repayment profile?
- Who are the major institutional holders, and what does 13F activity show about recent positioning?
ZTS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Zoetis Inc. (ZTS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 15h ago
Zoetis (ZTS) Stock May Trade At A Discount As Q2 Pressure Persists Yahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Trefis • 18h ago
Can Zoetis Stock Jump 30%? Trefis report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 21h ago
Zoetis: Weakening Fundamentals Overshadow The Discount (NYSE:ZTS) Seeking Alpha report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know Yahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Zoetis Inc (ZTS) Stock Up 4.2% and Still Undervalued -- GF Score: 71/100 GuruFocus report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 1d ago
Zoetis (NYSE:ZTS) Dividend Quality Backed by Strong Profitability and Health Ratings ChartMill report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
3 Reasons ZTS is Risky and 1 Stock to Buy Instead Yahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Zoetis (ZTS) Board Update And Dividend Keep Undervalued Narrative In Focus Yahoo Finance report covering Zoetis Inc. (ZTS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ZTS Bull vs. Bear Conversation Board — What's Your Call at $79.72?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZTS 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $85.10 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ZTS (C+ • RQD 67/100) a Buy at $78.80?
Welcome to the ZTS (Zoetis Inc.) Roar Pit. Current RQD Composite is 67/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (25.7% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $63.83 (-19.0%)
Spot @ $78.80 Pump the brakes on ZTS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ZTS, but look at what you are paying: 12.2x trailing P/E with 71.8% gross margins. Unless Zoetis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $100.08 (+27.0%)
Spot @ $78.80 ZTS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ZTS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $78.80 (52-wk range $68.77 - $144.83), any beat on forward guidance forces shorts and underweight funds to chase.